UiPath (NYSE:PATH) Hits Wall Street Target Ahead of Q2 ARR Challenge
6 August 2026

UiPath (NYSE:PATH) Hits Wall Street Target Ahead of Q2 ARR Challenge

NEW YORK, August 6, 2026, 05:04 EDT

  • UiPath finished at $13.82, rising 9.8% across five sessions.
  • The stock is currently in line with analysts’ consensus price target of $13.80.
  • Second quarter outlook suggests net new ARR of approximately $30.5 million, nearly unchanged from a year earlier.

UiPath stock has matched the average Wall Street price target following a rebound across the sector. Shares ended Wednesday at $13.82 and pointed to $13.70 ahead of U.S. market open. U.S. regular trading was yet to begin.

Stock chart for NYSE:PATH

Timing is key. Investors have already priced in the expected gains ahead of UiPath releasing its second-quarter results.

The company’s Q2 ARR midpoint is $1.9315 billion, indicating approximately $30.5 million in net new ARR, according to an initial estimate. UiPath recorded a $31 million net new ARR in the corresponding quarter a year ago.

The recent increase was largely not due to company-specific developments. UiPath saw its largest jump on Tuesday, coinciding with a rally in Palantir Technologies Inc. , which surged after reporting a near twofold rise in quarterly revenue and lifting its forecast.

SessionUiPath closing priceChange for the dayShares traded
July 29$12.59+3.28%62.57 million
August 4$14.10+8.05%61.99 million
August 5$13.82-1.99%91.84 million

Trading volume on Wednesday was 1.55 times greater than the 65-day average, indicating possible profit-taking following Tuesday’s sympathy move. The data does not confirm an end to the rally.

UiPath’s August 5 product update broadened complimentary Community access as part of Unified Pricing. The update introduced credits and licenses for agents, orchestration, and robotic automation. No financial information was included in the release.

MetricQ1 FY2027 actualQ2 FY2027 midpointQ2 FY2026 actual
Revenue$418 million$397.5 million$362 million
Revenue growth17%9.8%14%
ARR$1.901 billion$1.932 billion$1.723 billion
Net new ARR$49 million$30.5 million$31 million
Non-GAAP operating income$92 million$75 million$62 million
Non-GAAP operating margin22.0%18.9%17.1%

Q2 midpoint growth, net new ARR, and margin figures are initial estimates based on the company’s outlook.

Management gained trust in the first quarter as revenue climbed 17%, with GAAP operating income at $28 million. Chief Executive Daniel Dines stated that agentic products were “moving from pilot to production.” UiPath, Inc.

Even so, the Q2 outlook points to reduced revenue growth, with the midpoint indicating around 9.8%, compared to 17% in the previous quarter. Preliminary estimates suggest the non-GAAP margin will also decline sequentially.

Valuation provides a cushion, though it is not an unlimited one. As of April 30, UiPath had $1.42 billion in cash and securities, representing about 19% of its present market capitalisation.

Basic market-cap ratios are about 3.8 times ARR and 4.1 times projected yearly revenue. These figures are considered low for the software sector. However, the average analyst price target suggests no short-term gain.

CompanyLatest company growth signalMarket valueNear-term read-through
UiPathQ1 revenue up 17%$7.29 billionQ2 midpoint points to roughly 9.8%
Palantir Technologies Q2 revenue climbed 93%$406.96 billionAnnual forecast increased
ServiceNow Inc. Q2 revenue rose 24%$121.25 billionAI annual contract value topped $1 billion
Appian Corp. Q2 revenue projected to rise 12%-14%$2.21 billionResults expected before Thursday opening

The analysis is based on current market capitalisations and the most recent available growth indicators for each firm. Appian’s statistic reflects its guidance issued ahead of earnings.

UiPath continues to be much smaller than the top AI software leaders. Its growth rate also lags behind these firms. This difference accounts for its cheaper valuation and conservative analyst forecasts.

Analyst measureCurrent readingVersus $13.82 close
Buy recommendations2 of 1711.8%
Hold recommendations14 of 1782.4%
Sell recommendations1 of 175.9%
Average target$13.80-0.1%
Target range$12 to $18-13.2% to +30.2%

The consensus on recommendations stays solidly neutral.

Needham’s Scott Berg has set a price target of $15, suggesting an approximate 8.5% potential gain. A quarter in line with guidance could offer limited justification for raising targets more broadly.

Appian will announce results ahead of Thursday’s session, providing further insight into workflow demand. On Friday, the U.S. employment report will serve as a broader valuation gauge for software stocks.

Risks: UiPath’s outlook might be cautious, and accelerated pilot conversions have potential to boost ARR. However, a downturn in renewals, pricing challenges, or a broader software market decline could overturn the recovery.

UiPath requires more than consistent performance. An ARR outcome close to $1.932 billion would indicate steadiness. A convincing beat is necessary to support the recent rerating.

TS2 TECH • EXTENDED COVERAGE

Further analysis

What does UiPath need to report in its upcoming quarterly results?
The forecast for fiscal Q2 projects revenue between $395 million and $400 million, representing a year-on-year increase of 9% to 10% compared to last year's $362 million. Annual recurring revenue (ARR) is expected between $1.929 billion and $1.934 billion, indicating roughly 12% growth. Non-GAAP operating income is anticipated to be about $75 million.
Has robust first-quarter performance led to a meaningful upgrade of the outlook for the full year?
Revenue climbed 17% to $418 million, while ARR increased 12% to $1.901 billion. UiPath boosted its fiscal-2027 revenue forecast by $22 million to a new range of $1.776–$1.781 billion. The company also raised its non-GAAP operating income guidance, now up $15 million to approximately $430 million. The updated revenue forecast continues to suggest about 10% growth year over year.
Has agentic AI demonstrated quantifiable growth in customer numbers so far?
Dollar-based net retention stood at 109%, a slight increase from 108% in the prior year. Growth in ARR was driven 70% by existing customers and 30% by new additions. UiPath did not disclose revenue or ARR figures for agentic products separately. The specific impact from AI is still unclear.
What portion of the profit increase remains under GAAP accounting?
GAAP operating income came in at $28 million. Net income totaled $22.5 million. Non-GAAP operating income stood at $92.5 million. Stock-based compensation amounted to $53.3 million, equating to 12.7% of revenue. Operating cash flow was robust at $131.9 million.
Do share buybacks strengthen per-share performance without compromising liquidity?
UiPath bought back 20.4 million shares for $243.8 million over the quarter, paying an average of $11.47 per share, compared to the $13.82 closing price on Wednesday. Diluted weighted shares decreased 3.8% from a year ago. Cash and securities dropped 16% to $1.416 billion. As of April 30, $436.9 million was still available under its repurchase authorization.
Jerzy Lewandowski

Jerzy Lewandowski is a senior markets editor at TS2.tech covering stocks, artificial intelligence, semiconductors and global financial markets. He studied economics at the University of Warsaw and previously worked in investment analysis before moving into financial journalism. His daily coverage focuses on the trends and events that matter most to investors worldwide. Follow Jerzy Lewandowski on Google News.

AI PORTFOLIO

Top Stock Picks

Today’s highest-ranked model selections.

#1 STRONG BUY

CACI International

NYSE: CACI 95 / 100
#2 BUY

Walt Disney

NYSE: DIS 92 / 100
#3 BUY

AerCap

NYSE: AER 91 / 100
#4 ACCUMULATE

Occidental Petroleum

NYSE: OXY 88 / 100
#5 BUY ON WEAKNESS

MercadoLibre

NASDAQ: MELI 86 / 100
View full portfolio
Editorial model selection. Not personalised advice.
Intel shares end at $91 amid foundry unit lag despite surge in AI server sales
Previous Story

Intel Shares Fall Beneath $100 as 2026 Earnings Forecasts Surge 38%

JPMorgan Chase (NYSE:JPM) fraud-claim scrutiny weighs on stock at analysts’ target
Next Story

JPMorgan Chase (NYSE:JPM) fraud-claim scrutiny weighs on stock at analysts’ target